Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Rommelfanger2011 - Generalized logistic model of melanoma tumor therapy with vesicular stomatitis virus

ABSTRACT: This mathematical model is described by the publication: Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. "Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling". Gene Ther. 2012 May;19(5):543-9. doi: 10.1038/gt.2011.132. Curation Comment: Plots could not be reproduced as initial conditions for the simulations could not be found in the publication, nor estimated.

DISEASE(S): Melanoma

SUBMITTER: Emilia Chen

PROVIDER: MODEL2109110004 | BioModels | 2021-09-11

REPOSITORIES: BioModels

ACCESS DATA

Json Xml

Publications

Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling.

Rommelfanger D M DM Offord C P CP Dev J J Bajzer Z Z Vile R G RG Dingli D D

Gene therapy 20110915 5

Tumor selective, replication competent viruses are being tested for cancer gene therapy. This approach introduces a new therapeutic paradigm due to potential replication of the therapeutic agent and induction of a tumor-specific immune response. However, the experimental outcomes are quite variable, even when studies utilize highly inbred strains of mice and the same cell line and virus. Recognizing that virotherapy is an exercise in population dynamics, we utilize mathematical modeling to under ...[more]

PMID: 21918546

Similar Datasets

Rommelfanger2011 - Gompertz model of melanoma tumor therapy with vesicular stomatitis virus

Project description:This mathematical model is described by the publication: Rommelfanger DM, Offord CP, Dev J, Bajzer Z, Vile RG, Dingli D. "Dynamics of melanoma tumor therapy with vesicular stomatitis virus: explaining the variability in outcomes using mathematical modeling". Gene Ther. 2012 May;19(5):543-9. doi: 10.1038/gt.2011.132. Curation Comment: Plots could not be reproduced as initial conditions for the simulations could not be found in the publication, nor estimated.

2021-09-11 | MODEL2109110003 | BioModels

Pulmonary melanoma metastasis

Project description:This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/In this experiment, we have injected mice with fluorescent melanoma cells and then collected their lungs 1-3 days later and run them through a flow cytometer to separate the fluorescent cells (i.e., the melanoma cells) from the non-sluprescent cells (i.e., the lung cells) so we can sequence their transcriptomes to identify the transciptional profiles associated with pulmonary melanoma metastasis.

2014-08-20 | E-ERAD-287 | biostudies-arrayexpress

Mouse melanoma cell lines transcriptome sequencing

Project description:n this project we have sequenced the transcriptome of several comonly used mouse melanoma cell lines. Our aim is to understand what mutations and rearrangements are found in these cell lines to gain a better understanding of the genes that contribute to melanomagenesis. As these cell lines are used as models of melanoma these sequences represent an important resource for functional studies. This data is part of a pre-publication release. For information on the proper use of pre-publication data shared by the Wellcome Trust Sanger Institute (including details of any publication moratoria), please see http://www.sanger.ac.uk/datasharing/

2015-01-17 | E-ERAD-94 | biostudies-arrayexpress

M249 melanoma cells: Vemurafenib and Selumetinib resistant through BRAF double minutes vs. parental

Project description:CGH profiling of M249 melanoma cell line treated with step-wise increasing Vemurafenib and Selumetinib to develop resistance (VSR). The resistance mechanims was through BRAF amplification in double minute (DM) format. The control cell line is untreated M249.

2021-12-20 | GSE153526 | GEO

Expression analysis of zebrafish melanoma and skin from the mitf-BRAFV600E;p53-/- line

2011-03-30 | GSE24528 | GEO

Expression analysis of zebrafish melanoma and skin from the mitf-BRAFV600E;p53-/- line

Project description:Investigation of expression differences between skin and melanomas from a transgenic BRAFV600E zebrafish model of melanoma The embryos described in this study are further analyzed in a manuscript submitted for publication by White, et al. A 15 chip study using RNA extracted from either WT zebrafish skin, mitf-BRAFV600E;p53-/- skin or mitf-BRAFV600E;p53-/- melanoma

2011-03-30 | E-GEOD-24528 | biostudies-arrayexpress

High Response Rate to Anti PD-1 Therapy in Desmoplastic Melanoma

Project description:<p>Desmoplastic melanoma (DM) is a rare subtype of melanoma characterized by dense fibrous stroma, resistance to chemotherapy and a lack of actionable driver mutations, but is highly associated with ultraviolet light DNA damage. We analysed 60 patients with advanced DM treated with programmed cell death 1 (PD-1) or PD-1 ligand (PD-L1) blocking antibody therapy. Objective tumor responses were observed in 42 of the 60 patients (70%, 95% confidence interval 57-81%), including 19 patients (32% overall) with a complete response. Whole-exome sequencing revealed a high mutational load and frequent NF-1 mutations (14 out of 17 cases). Immunohistochemistry (IHC) analysis from 19 DM and 13 non-DM revealed a higher percentage of PD-L1 positive cells in the tumor parenchyma in DM (p = 0.04), highly associated with increased CD8 density and PD-L1 expression in the tumor invasive margin. Therefore, patients with advanced DM derive significant clinical benefit from PD-1/PD-L1 immune checkpoint blockade therapy despite being a cancer defined by its dense desmoplastic fibrous stroma. The benefit is likely derived from the high mutational burden and a frequent pre-existing adaptive immune response limited by PD-L1 expression.</p>

| phs001469 | dbGaP

Cisplatin treated melanoma and melanocyte cell lines

Project description:Nucleotide excision repair (NER) orchestrates the repair of helix distorting DNA damage, induced by both ultraviolet radiation (UVR) and cisplatin. There is evidence that the global genome repair (GGR) arm of NER is dysfunctional in melanoma and it is known to have limited induction in melanoma cell lines after cisplatin treatment. The aims of this study were to examine mRNA transcript levels of regulators of GGR and to investigate the downstream effect on global transcript expression in melanoma cell lines after cisplatin treatment and in melanoma tumours. One melanocyte, three primary melanoma (MM200, IgR3, Me4405) and two metastatic melanoma (Mel-RM and Sk-mel-28) cell lines were treated with cispltain and gene expression profile data collected at 0, 6 and 24 hours. Biological duplicates were treated and RNA was collected for each cell line at each timepoint. The duplicated were run sperately on the WGGEX beadarrays and the results of the duplicates averaged for publication. The transcript expression results were cubic spline normalised using BeadStudio 2.0 software (Illumina, USA), and the remaining analyses was performed using GeneSpring GX 11.0. To account for bias or skewing of expression results all the gene expression profiles and each individual gene were normalized to the median resulting in two way normalisation. For visualisation of the results the data was log transformed.

2013-07-01 | E-GEOD-47980 | biostudies-arrayexpress

The miRNA profiles of plasma extracellular vesicles (pEV) in melanoma patients and supernatant EV (sEV) of related cell cultures

Project description:The dataset contains miRNA pEV profiles measured on Agilent Microarrays from three groups of melanoma patients (before or at resection, and after resection categorized into high-risk and low-risk groups) and healthy controls. These groups were compared to find differentially abundant miRNAs in the pEV of melanoma patients. In addition, two comparisons of short-term profile changes around the resection date are included, as well as six cell line sEV that play a role for the accompanying publication.

2019-03-05 | GSE100508 | GEO

MITF drives endolysosomal biogenesis and potentiates Wnt signaling in melanoma cells

Project description:Canonical Wnt signaling plays an important role in development and disease, regulating transcription of target genes and stabilizing many proteins phosphorylated by Glycogen Synthase Kinase 3 (GSK3). We observed that the MiT family of transcription factors, which includes the melanoma oncogene MITF and the lysosomal master regulator TFEB, had the highest phylogenetic conservation of three consecutive putative GSK3 phosphorylation sites in animal proteomes. This prompted us to examine the relationship between MITF, endolysosomal biogenesis and Wnt signaling. Here we report that MITF expression levels correlated with the expression of a large subset of lysosomal genes in melanoma cell lines. MITF expression in the Tetracycline-inducible C32 melanoma model caused a marked increase in vesicular structures, and increased expression of late endosomal proteins such as Rab7, LAMP1, and CD63. These late endosomes were not functional lysosomes as they were less active in proteolysis, yet were able to concentrate Axin1, phospho-LRP6, phospho-β-Catenin, and GSK3 in the presence of Wnt ligands. This relocalization significantly enhanced Wnt signaling by increasing the number of multivesicular bodies (MVBs) into which the Wnt signalosome/destruction complex becomes localized upon Wnt signaling. We also show that the MITF protein was stabilized by Wnt signaling, through the novel C-terminal GSK3 phosphorylations identified here. MITF stabilization caused an increase in MVB biosynthesis, which in turn increased Wnt signaling, generating a positive feed-back loop that may function during the proliferative stages of melanoma. The results underscore the importance of misregulated endolysosomal biogenesis in Wnt signaling and cancer. Expression of selected Lysosomal genes and CLEAR element plus MITF were compared in 51 melanoma cell lines to a mixed reference pool containing equal amounts of 47 melanoma cell lines.

2014-12-24 | E-GEOD-64497 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data